HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-03-24FDA Approved: VIRACEPT — Supplemental Application (AGOURON)
FDA approved a supplemental application for VIRACEPT (nelfinavir mesylate) from Agouron.
-
FDA approval · 2021-03-23FDA Approved: TIVICAY PD — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for Tivicay PD (dolutegravir) filed by ViiV Healthcare Company.
-
FDA approval · 2021-03-23FDA Approved: TIVICAY — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for Tivicay (dolutegravir) from ViiV Healthcare Company.
-
FDA approval · 2021-03-23FDA Approved: TRIUMEQ — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for TRIUMEQ (abacavir sulfate, dolutegravir sodium, lamivudine) from ViiV Healthcare Company.
-
FDA approval · 2021-03-23FDA Approved: JULUCA — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for JULUCA (dolutegravir + rilpivirine) from ViiV Healthcare Company.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-03-23FDA Approved: DOVATO — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for DOVATO (dolutegravir and lamivudine) from ViiV Healthcare Company.
-
CLINICAL_TRIALS trial_result · 2021-03-23Clinical Trial Update: Clinical Phenotyping and Genotyping of HIV-Associated Sensory Neuropathy: The HIV-POGO Study
Clinical trial update describing phenotyping and genotyping of HIV-associated sensory neuropathy (HIV-POGO) completing enrollment with resul…
-
FDA approval · 2021-03-22FDA Approved: DRONABINOL — Supplemental Application (Wellhouse Pharma, LLC)
FDA approved a supplemental application for dronabinol from Wellhouse Pharma, LLC.
-
CLINICAL_TRIALS trial_result · 2021-03-17Clinical Trial Update: Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir [Phase 2, Phase 3]
A completed Phase 2/3 trial evaluating switching from a nevirapine-based regimen to once-daily rilpivirine/emtricitabine/tenofovir for HIV.
-
CLINICAL_TRIALS trial_result · 2021-03-17Clinical Trial Update: Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers [NA]
A completed clinical trial assessing the interaction potential between dolutegravir and simeprevir in HIV/HCV seronegative volunteers.
-
CLINICAL_TRIALS trial_result · 2021-03-11Clinical Trial Update: Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1 [Phase 3]
Phase 3 trial updating treatment-experienced, multi-drug resistant HIV-1 patients with ibalizumab plus an optimized background regimen compl…
-
FDA approval · 2021-03-08FDA Approved: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for a generic emtricitabine and tenofovir disoproxil fumarate product from Zydus Pharmaceuticals USA…
-
CLINICAL_TRIALS trial_result · 2021-03-05Clinical Trial Update: HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) [Phase 4]
Phase 4 trial assessing HPV vaccination after treatment of anal intraepithelial neoplasia (AIN) in individuals with HIV.
-
FDA approval · 2021-03-04FDA Approved: GENVOYA — Supplemental Application (Gilead Sciences, Inc.)
The FDA page documents a supplemental application submission for GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide…
-
FDA approval · 2021-03-04FDA Approved: ODEFSEY — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for ODEFSEY (emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide) from Gilead Sc…
-
FDA approval · 2021-03-04FDA Approved: DESCOVY — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for DESCOVY (emtricitabine and tenofovir alafenamide) from Gilead, updating the product labeling…
-
FDA approval · 2021-03-04FDA Approved: BIKTARVY — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for BIKTARVY, submitted by Gilead Sciences, Inc.
-
CLINICAL_TRIALS trial_result · 2021-03-04Clinical Trial Update: A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1 [Phase 3]
Phase 3 trial update for continued access to TMC278-TIDP6-C222 in HIV-1 infected patients; study completed with results posted.
-
FDA approval · 2021-03-01FDA Approved: DOVATO — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for DOVATO, a fixed-dose combination of dolutegravir and lamivudine, developed by ViiV Healthcare.
-
FDA approval · 2021-03-01FDA Approved: TRIUMEQ — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental NDA for TRIUMEQ (abacavir sulfate, dolutegravir, lamivudine) from ViiV Healthcare Company.
-
CLINICAL_TRIALS trial_result · 2021-02-25Clinical Trial Update: A Pilot Intervention to Improve Coping With Discrimination and Adherence Among HIV-Positive Latino MSM [NA]
A completed clinical trial evaluating a pilot intervention to improve coping with discrimination and adherence among HIV-positive Latino men…
-
FDA approval · 2021-02-24FDA Approved: BIKTARVY — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for BIKTARVY (bictegravir/emtricitabine/tenofovir alafenamide) from Gilead, reflecting an update…
-
CLINICAL_TRIALS trial_result · 2021-02-23Clinical Trial Update: Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults [Phase 1]
This Phase 1 open-label study evaluated the safety, tolerability, pharmacokinetics, and virologic effects of two HIV broadly neutralizing an…
-
CLINICAL_TRIALS trial_result · 2021-02-23Clinical Trial Update: Defining the PrEP Care Continuum Among Recently Incarcerated Men at High-Risk for HIV Infection [Phase 4]
Phase 4 trial update investigating the PrEP care continuum among recently incarcerated men at high risk for HIV infection.
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection [Phase 4]
Phase 4 trial update evaluating time to protection and adherence requirements of raltegravir with or without lamivudine for HIV infection pr…